消化

晚期肝癌的预后:巴塞罗那临床肝癌C期的新分层:法国一项多中心研究的结果

作者:陈亚云 编译 来源:医学论坛网 日期:2016-05-24
导读

         Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study Adhoute, Xavier; Pnaranda, Guillaume; Raoul, Jea

Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study

Adhoute, Xavier; Pénaranda, Guillaume; Raoul, Jean L.; Blanc, Jean F.; Edeline, Julien; Conroy, Guillaume; Perrier, Hervé; Pol, Bernard; Bayle, Olivier; Monnet, Olivier; Beaurain, Patrick; Muller, Cyril; Castellani, Paul; Bronowicki, Jean-Pierre; Bourlière, Marc

Abstract

Background: Advanced hepatocellular carcinoma (HCC) includes a wide spectrum of tumors and patients’ prognosis after treatment is highly variable. Moreover, therapeutic options based on the Barcelona Clinic Liver Cancer (BCLC) staging system algorithm are restricted to one systemic therapy.

Aim of the study: To refine the stratification among BCLC C HCC patients by establishing a new simple prognostic score.

Patients and methods: A regression model based on a BCLC stage C population and validated with an external cohort of BCLC C HCC patients defined the score. It was therefore validated among three external cohorts of BCLC C HCC patients treated with sorafenib.

Results: Five variables had independent prognostic values: the number of nodules, the infiltrating nature of the HCC, α-fetoprotein serum level, Child–Pugh score, and Eastern Cooperative Oncology Group Performance Status grade. They were integrated into a new score named NIACE ranging from 0 to 7, well correlated with survival. With the use of one threshold value, this score enables defining of two populations with different survivals among BCLC C patients and specifically among those treated with sorafenib.

Conclusion: The NIACE score defines different prognostic subgroups after palliative treatment of HCC. It could be an additional tool for BCLC C HCC before inclusion in clinical trials or for the management of patients. These results must be validated in a prospective study.

European Journal of Gastroenterology & Hepatology:

April 2016 - Volume 28 - Issue 4 - p 433–440

 

分享:

相关文章

评论

我要跟帖
发表
回复 小鸭梨
发表

copyright©医学论坛网 版权所有,未经许可不得复制、转载或镜像

京ICP证120392号  京公网安备110105007198  京ICP备10215607号-1  (京)网药械信息备字(2022)第00160号
//站内统计 //百度统计 //谷歌统计 //站长统计
*我要反馈: 姓    名: 邮    箱: